Form 8-K - Current report:
SEC Accession No. 0001493152-25-017931
Filing Date
2025-10-14
Accepted
2025-10-14 08:15:33
Documents
14
Period of Report
2025-10-14
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 45262
2 EX-99.1 ex99-1.htm EX-99.1 27688
  Complete submission text file 0001493152-25-017931.txt   289338

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cing-20251014.xsd EX-101.SCH 3760
4 XBRL DEFINITION FILE cing-20251014_def.xml EX-101.DEF 26604
5 XBRL LABEL FILE cing-20251014_lab.xml EX-101.LAB 36654
6 XBRL PRESENTATION FILE cing-20251014_pre.xml EX-101.PRE 25228
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5659
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 251389822
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)